Novartis AG (LSE:0HKE)
£ 3657.04 0 (0%) Market Cap: 60.95 Bil Enterprise Value: 74.78 Bil PE Ratio: 14.34 PB Ratio: 5.34 GF Score: 77/100

Novartis AG at UBS Global Healthcare Conference (Virtual) Transcript

May 20, 2020 / 12:20PM GMT
Laura Sutcliffe
UBS Investment Bank, Research Division - Equity Research Analyst

Good morning, everyone. Welcome to the last day of the UBS Global Healthcare Conference. Thank you for being with us. My name is Laura Sutcliffe. I cover Novartis here at UBS, and I'm delighted to be joined by Susanne Schaffert, who's the CEO of Novartis Oncology.

We've got about 40 minutes. I will ask Susanne to kick off with some opening remarks, which I don't think will take very long, and then we'll jump into Q&A. I have some prepared, but if you'd like to ask a question yourself, you can do that via the webcast. If that's not working for you, you can always drop me an e-mail, [email protected]. And we'll try to get through as many of them as we can.

So with that, I will hand you to Susanne for a few opening comments.

Susanne Schaffert
Novartis AG - President of Novartis Oncology

Thank you so much, Laura, and thanks, everybody, for joining. So let me give a few introductory remarks, and then we get right into the Q&A.

So we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot